End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.73 USD | +4.27% | +4.37% | +100.35% |
04-24 | Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis | CI |
04-01 | Top Premarket Decliners | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 64.01M 5.12B |
---|---|---|---|---|---|
Net income 2024 * | -26M -2.08B | Net income 2025 * | -35M -2.8B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.6
x | P/E ratio 2025 * |
-2.7
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.09% |
1 day | +4.27% | ||
1 week | +4.37% | ||
1 month | +45.80% | ||
3 months | -7.58% | ||
6 months | +166.51% | ||
Current year | +100.35% |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 5.96 | +4.01% | 20,928 |
30/04/24 | 5.73 | +4.27% | 19,710 |
29/04/24 | 5.495 | +0.83% | 15,627 |
26/04/24 | 5.45 | +3.02% | 8,939 |
25/04/24 | 5.29 | -3.64% | 18,095 |
End-of-day quote Nasdaq, April 29, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+100.35% | 64.01M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+5.01% | 22.25B | |
-14.77% | 21.68B | |
-8.63% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- CALC Stock